David Colpman
CIK: 0001818776
David Colpman's purchase track record
How the stock did after each of David Colpman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 15, 2022
Stock higher 6 months later
67%
3 months: 100%
Median 6-month return
+50.7%
3 months: +57.5%
Beat the S&P 500
67%
median +39.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/17/2025 | ELUT | $6K | +113.9% | +96.2% | +10.4% |
| 11/17/2025 | ELUT | $11K | +57.5% | +50.7% | +10.9% |
| 12/15/2022 | ELUT | $12K | +11.9% | -37.5% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ELUT | ▲ Buy | Open Market | 12,500 | $6K | 12/17/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 15,500 | $11K | 11/17/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 3,098 | $12K | 12/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.